The FDA has approved Lutathera, marking the first time that the agency has given approval for a radioactive drug or ‘radiopharmaceutical’.
The treatment is designed for a rare type of cancer of the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
